EXTX — Exact Therapeutics AS Cashflow Statement
0.000.00%
Last trade - 00:00- NOK91.10m
- NOK67.19m
Annual cashflow statement for Exact Therapeutics AS, fiscal year end - December 31st, NOK millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -58.6 | -40.1 | -48.3 | -52.3 | -87 |
| Depreciation | |||||
| Non-Cash Items | 2.53 | -0.607 | 3.96 | 2.21 | 4.35 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.88 | 4.92 | -2.01 | -32.9 | 11.9 |
| Change in Accounts Receivable | |||||
| Change in Payable / Accrued Expenses | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -55.1 | -33.9 | -44.3 | -80.5 | -67 |
| Capital Expenditures | -1.63 | -0.251 | -3.09 | -1.51 | -5.32 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.616 | 20.9 | 0.945 | 0.925 | 2.62 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Change in Net Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -1.01 | 20.6 | -2.15 | -0.581 | -2.7 |
| Financing Cash Flow Items | -0.117 | -0.12 | -1.25 | -10.1 | -0.035 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -0.047 | -0.531 | 23.2 | 134 | -0.795 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -56.3 | -13.5 | -23 | 53.1 | -75.2 |